Capital Investment Advisors’s AbbVie ABBV Stock Holding History

Capital Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$71.9M	Buy	330,429 +17,365	+6%	+$3.85M	1.05%	26
2025 Q4	$71.5M	Buy	313,064 +7,114	+2%	+$1.62M	1.09%	24
2025 Q3	$70.8M	Buy	305,950 +114,177	+60%	+$23.3M	1.16%	24
2025 Q2	$35.6M	Buy	191,773 +2,678	+1%	+$498K	0.64%	46
2025 Q1	$39.6M	Sell	189,095 -1,422	-0.7%	-$276K	0.78%	36
2024 Q4	$33.9M	Buy	190,517 +2,183	+1%	+$401K	0.69%	42
2024 Q3	$37.2M	Buy	188,334 +382	+0.2%	+$71.3K	0.77%	36
2024 Q2	$32.2M	Buy	187,952 +3,208	+2%	+$531K	0.73%	39
2024 Q1	$33.6M	Buy	184,744 +1,082	+0.6%	+$186K	0.78%	35
2023 Q4	$28.5M	Buy	183,662 +561	+0.3%	+$81.8K	0.71%	36
2023 Q3	$27.3M	Sell	183,101 -1,180	-0.6%	-$173K	0.76%	35
2023 Q2	$24.8M	Sell	184,281 -2,686	-1%	-$394K	0.76%	37
2023 Q1	$29.8M	Buy	186,967 +4,101	+2%	+$627K	0.88%	29
2022 Q4	$29.6M	Buy	182,866 +3,064	+2%	+$470K	0.89%	28
2022 Q3	$24.1M	Buy	179,802 +7,404	+4%	+$1.06M	0.83%	31
2022 Q2	$26.4M	Buy	172,398 +1,973	+1%	+$301K	0.88%	32
2022 Q1	$27.6M	Sell	170,425 -334	-0.2%	-$48.5K	0.84%	30
2021 Q4	$23.1M	Buy	170,759 +4,884	+3%	+$577K	0.71%	34
2021 Q3	$17.9M	Buy	165,875 +9,247	+6%	+$1.06M	0.6%	41
2021 Q2	$17.6M	Buy	156,628 +9,041	+6%	+$1.02M	0.61%	41
2021 Q1	$16M	Buy	147,587 +11,963	+9%	+$1.28M	0.6%	42
2020 Q4	$14.5M	Buy	135,624 +9,353	+7%	+$899K	0.61%	44
2020 Q3	$11.1M	Buy	126,271 +6,653	+6%	+$626K	0.53%	48
2020 Q2	$11.7M	Buy	119,618 +12,832	+12%	+$1.13M	0.61%	41
2020 Q1	$8.14M	Sell	106,786 -2,041	-2%	-$174K	0.52%	48
2019 Q4	$9.64M	Buy	108,827 +7,469	+7%	+$620K	0.47%	55
2019 Q3	$7.67M	Buy	101,358 +21,943	+28%	+$1.5M	0.4%	67
2019 Q2	$5.78M	Buy	79,415 +17,396	+28%	+$1.37M	0.32%	81
2019 Q1	$5M	Buy	62,019 +14,469	+30%	+$1.18M	0.29%	80
2018 Q4	$4.38M	Buy	47,550 +9,333	+24%	+$821K	0.29%	81
2018 Q3	$3.62M	Buy	38,217 +3,444	+10%	+$327K	0.21%	95
2018 Q2	$3.22M	Buy	34,773 +7,546	+28%	+$737K	0.2%	101
2018 Q1	$2.58M	Buy	27,227 +852	+3%	+$93.6K	0.17%	119
2017 Q4	$2.55M	Sell	26,375 -6,212	-19%	-$585K	0.17%	122
2017 Q3	$2.9M	Buy	32,587 +7,257	+29%	+$552K	0.2%	113
2017 Q2	$1.84M	Buy	25,330 +868	+4%	+$58.4K	0.13%	140
2017 Q1	$1.59M	Sell	24,462 -1,194	-5%	-$75.1K	0.12%	152
2016 Q4	$1.61M	Buy	25,656 +657	+3%	+$40.1K	0.14%	147
2016 Q3	$1.58M	Sell	24,999 -915	-4%	-$59.2K	0.14%	146
2016 Q2	$1.6M	Buy	25,914 +9,074	+54%	+$553K	0.15%	130
2016 Q1	$962K	Buy	16,840 +8,055	+92%	+$449K	0.09%	177
2015 Q4	$520K	Sell	8,785 -117	-1%	-$6.74K	0.05%	240
2015 Q3	$484K	Sell	8,902 -157	-2%	-$10.2K	0.05%	231
2015 Q2	$609K	Sell	9,059 -79	-0.9%	-$5.16K	0.07%	218
2015 Q1	$535K	Sell	9,138 -110	-1%	-$6.64K	0.06%	233
2014 Q4	$605K	Sell	9,248 -47	-0.5%	-$2.96K	0.07%	222
2014 Q3	$537K	Buy	9,295 +149	+2%	+$8.27K	0.06%	220
2014 Q2	$516K	Sell	9,146 -785	-8%	-$41.2K	0.06%	225
2014 Q1	$510K	Sell	9,931 -375	-4%	-$19K	0.06%	231
2013 Q4	$544K	Buy	+10,306	New	+$507K	0.07%	212

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Investment Advisors's ABBV Position: Q1 2026 in Review

Capital Investment Advisors increased its AbbVie (ABBV) stake by 5.5% in Q1 2026, buying an estimated $3.85M and bringing the position to 330,429 shares worth $71.9M. The position accounts for 1.05% of the portfolio, ranked #26.

Capital Investment Advisors first reported a position in ABBV in Q4 2013 and has held it in 50 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Capital Investment Advisors held 330,429 shares of AbbVie worth $71.9M as of Q1 2026.
Capital Investment Advisors bought 17,365 AbbVie shares in Q1 2026, an estimated $3.85M.
AbbVie made up 1.05% of Capital Investment Advisors's portfolio in Q1 2026, its #26 holding.
Capital Investment Advisors first reported a position in AbbVie in Q4 2013 and has held it in 50 quarters since.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.